Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H24N2O2.ClH |
Molecular Weight | 360.878 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C3=C4C=C(OC)C=CC4=NC=C3
InChI
InChIKey=LBSFSRMTJJPTCW-DSXUQNDKSA-N
InChI=1S/C20H24N2O2.ClH/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18;/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3;1H/t13-,14-,19-,20+;/m0./s1
DescriptionSources: https://onlinelibrary.wiley.com/doi/abs/10.1002/jps.3080010617http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021799s024lbl.pdfCurator's Comment: description was created based on several sources, including
http://www.fda.gov/downloads/ForHealthProfessionals/LearningActivities/UCM317816.pdf
Sources: https://onlinelibrary.wiley.com/doi/abs/10.1002/jps.3080010617http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021799s024lbl.pdf
Curator's Comment: description was created based on several sources, including
http://www.fda.gov/downloads/ForHealthProfessionals/LearningActivities/UCM317816.pdf
QUALAQUIN (quinine sulfate) is an antimalarial drug indicated only for treatment of uncomplicated Plasmodium falciparum malaria. It’s an alkaloid derived from the bark of the cinchona tree and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine sulfate has been shown to be effective in geographical regions where resistance to chloroquine has been documented. Quinine inhibits nucleic acid synthesis, protein synthesis, and glycolysis in Plasmodium falciparum and can bind with hemazoin in parasitized erythrocytes. However, the precise mechanism of the antimalarial activity of quinine sulfate is not completely understood. It is thought to act by inhibiting heme polymerase, thereby allowing accumulation of its cytotoxic substrate, heme. As a schizonticidal drug, it is less effective and more toxic than chloroquine. Quinine is FDA-approved. It is not considered safe and effective for the treatment or prevention of leg cramps-- an "off-label" (non-FDA-approved) use. Quinine is associated with serious and life-threatening adverse events, including: thrombocytopenia, hypersensitivity reactions, and QT prolongation. Thrombocytopenia associated with the use of quinine for the treatment or prevention of leg cramps includes: immune thrombocytopenic purpura, hemolytic uremic syndrome, thrombotic thrombocytepenic purpura with associated renal insufficiency.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL613897 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14967191 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | QUALAQUIN Approved Useis a cinchona alkaloid indicated for treatment of uncomplicated Plasmodium falciparum malaria Launch Date2005 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.2 μg/mL |
8.7 mg/kg single, oral dose: 8.7 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
QUININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
28 μg × h/mL |
8.7 mg/kg single, oral dose: 8.7 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
QUININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12.5 h |
8.7 mg/kg single, oral dose: 8.7 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
QUININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8% |
8.7 mg/kg single, oral dose: 8.7 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
QUININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
5 g single, oral |
unhealthy, 17 years n = 1 Health Status: unhealthy Age Group: 17 years Sex: M Population Size: 1 Sources: |
Other AEs: Respiratory distress... |
1.8 g single, oral Overdose |
unhealthy, 46 years n = 1 Health Status: unhealthy Age Group: 46 years Sex: F Population Size: 1 Sources: |
Other AEs: Hearing loss... |
16250 mg single, oral Overdose Dose: 16250 mg Route: oral Route: single Dose: 16250 mg Sources: |
unhealthy, 49 years n = 1 Health Status: unhealthy Age Group: 49 years Sex: F Population Size: 1 Sources: |
Other AEs: Cardiotoxicity... |
9.75 g single, oral |
unhealthy, adult n = 1 Health Status: unhealthy Age Group: adult Sex: M Population Size: 1 Sources: |
Other AEs: Tachycardia... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Respiratory distress | grade 5, 1 patient | 5 g single, oral |
unhealthy, 17 years n = 1 Health Status: unhealthy Age Group: 17 years Sex: M Population Size: 1 Sources: |
Hearing loss | 1 patient | 1.8 g single, oral Overdose |
unhealthy, 46 years n = 1 Health Status: unhealthy Age Group: 46 years Sex: F Population Size: 1 Sources: |
Cardiotoxicity | 1 patient | 16250 mg single, oral Overdose Dose: 16250 mg Route: oral Route: single Dose: 16250 mg Sources: |
unhealthy, 49 years n = 1 Health Status: unhealthy Age Group: 49 years Sex: F Population Size: 1 Sources: |
Tachycardia | grade 5 | 9.75 g single, oral |
unhealthy, adult n = 1 Health Status: unhealthy Age Group: adult Sex: M Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Olfactory learning induces differential long-lasting changes in rat central olfactory pathways. | 2001 |
|
Patterns of Plasmodium falciparum drug resistance in nonimmune travellers to Africa. | 2001 Apr |
|
Simultaneous separation of the stereoisomers of 1-amino-2-hydroxy and 2-amino-1-hydroxypropane phosphonic acids by stereoselective capillary electrophoresis employing a quinine carbamate type chiral selector. | 2001 Apr |
|
HPTLC method for the estimation of alkaloids of Cinchona officinalis stem bark and its marketed formulations. | 2001 Apr |
|
Use of the DELI-microtest to determine the drug sensitivity of Plasmodium falciparum in Burkina Faso. | 2001 Apr |
|
Muscimol infusions in the brain stem reticular formation reversibly block ingestion in the awake rat. | 2001 Apr |
|
Role of parabrachial nucleus in submandibular salivary secretion induced by bitter taste stimulation in rats. | 2001 Apr 12 |
|
Simultaneous determination of quinine and four metabolites in plasma and urine by high-performance liquid chromatography. | 2001 Apr 15 |
|
Severe babesiosis in Long Island: review of 34 cases and their complications. | 2001 Apr 15 |
|
Soa genotype selectively affects mouse gustatory neural responses to sucrose octaacetate. | 2001 Apr 27 |
|
Quinine-induced thrombocytopenia in a 64-year-old man who consumed tonic water to relieve nocturnal leg cramps. | 2001 Aug |
|
5-HT1A receptor-mediated activation of G-protein-gated inwardly rectifying K+ current in rat periaqueductal gray neurons. | 2001 Aug |
|
Ferrocene-chloroquine analogues as antimalarial agents: in vitro activity of ferrochloroquine against 103 Gabonese isolates of Plasmodium falciparum. | 2001 Aug |
|
Role of quinine-sensitive ion channels in volume regulation in boar and bull spermatozoa. | 2001 Aug |
|
Large-conductance calcium-activated potassium channels in neonatal rat intracardiac ganglion neurons. | 2001 Feb |
|
Determination of cisapride in pharmaceutical preparations using derivative spectrophotometry. | 2001 Feb |
|
In vitro antiplasmodial activity of 4-phenylcoumarins from Exostema mexicanum. | 2001 Feb |
|
Reduction of saltiness and bitterness after a chlorhexidine rinse. | 2001 Feb |
|
Delayed quinine toxicity mimicking open angle glaucoma. | 2001 Feb |
|
Computer-simulation studies on roles of potassium currents in neurotransmission of the auditory nerve. | 2001 Feb |
|
Activation of ion-conducting pathways in the inner mitochondrial membrane - an unrecognized activity of fatty acid? | 2001 Feb 23 |
|
Taste receptor cells that discriminate between bitter stimuli. | 2001 Feb 23 |
|
Ethanol perception and ingestion. | 2001 Jan |
|
Declining chloroquine resistance of Plasmodium falciparum in Lambaréné, Gabon from 1992 to 1998. | 2001 Jan 15 |
|
Effect of extracellular Ca2+ on the quinine-activated current of bullfrog taste receptor cells. | 2001 Jan 15 |
|
[Fulminant course of falciparum malaria]. | 2001 Jan 26 |
|
Covariation in individuals' sensitivities to bitter compounds: evidence supporting multiple receptor/transduction mechanisms. | 2001 Jul |
|
Apparent drug failure following artesunate treatment of Plasmodium falciparum malaria in Freetown, Sierra Leone: four case reports. | 2001 Jul |
|
Sapid solutions and food intake in repeated dehydration and rehydration periods in rats. | 2001 Jul |
|
Myosin II-dependent cylindrical protrusions induced by quinine in Dictyostelium: antagonizing effects of actin polymerization at the leading edge. | 2001 Jun |
|
Lateral parabrachial nucleus lesions in the rat: neophobia and conditioned taste aversion. | 2001 Jun |
|
The effect of laser assisted uvulopalatoplasty on the sense of smell and taste. | 2001 Jun |
|
Therapeutic efficacy of sulphadoxine/pyrimethamine and susceptibility in vitro of P. falciparum isolates to sulphadoxine-pyremethamine and other antimalarial drugs in Malawian children. | 2001 Jun |
|
Dynamic and multimodal responses of gustatory cortical neurons in awake rats. | 2001 Jun 15 |
|
Mechanisms by which intracellular calcium induces susceptibility to secretory phospholipase A2 in human erythrocytes. | 2001 Jun 22 |
|
Effects of hydroxypyridinone iron chelators in combination with antimalarial drugs on the in vitro growth of Plasmodium falciparum. | 2001 Mar |
|
Capillary electrophoretic separation, immunochemical recognition and analysis of the diastereomers quinine and quinidine and two quinidine metabolites in body fluids. | 2001 Mar |
|
[Treatment of acute malaria with quinine in a non-immunized patient: rationale for a 7-day regimen]. | 2001 Mar 17 |
|
Genomic and functional characteristics of novel human pancreatic 2P domain K(+) channels. | 2001 Mar 23 |
|
[Severe malaria]. | 2001 Mar 31 |
|
The treatment of babesiosis. | 2001 Mar 8 |
|
Characterization of TASK-4, a novel member of the pH-sensitive, two-pore domain potassium channel family. | 2001 Mar 9 |
|
Exchange transfusion for severe malaria. | 2001 Mar-Apr |
|
Interaction of gustatory and lingual somatosensory perceptions at the cortical level in the human: a functional magnetic resonance imaging study. | 2001 May |
|
Molecular cloning and characterization of a novel (Na+,K+)/H+ exchanger localized to the trans-Golgi network. | 2001 May 18 |
|
Resistance of Plasmodium falciparum to antimalarial drugs in a highly endemic area of southern Viet Nam: a study in vivo and in vitro. | 2001 May-Jun |
|
A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. | 2001 May-Jun |
|
Antimalarial activity of azithromycin, artemisinin and dihydroartemisinin in fresh isolates of Plasmodium falciparum in Thailand. | 2001 Sep 1 |
|
Optochin resistance in Streptococcus pneumoniae: mechanism, significance, and clinical implications. | 2001 Sep 1 |
|
HPLC of basic drugs on microparticulate strong cation-exchange materials - a review. | 2001 Sep 15 |
Sample Use Guides
in adults: 648 mg (two capsules) every 8 hours for 7 days
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27089323
Quinine (0-100 uM) stimulates adipogenesis through ERK/S6 (extracellular-signal-regulated kinase/Ribosomal protein S6) signaling, which at least partly functions via taste receptor, type 2, member 106 (T2R106)
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 310.547
Created by
admin on Fri Dec 15 16:45:49 GMT 2023 , Edited by admin on Fri Dec 15 16:45:49 GMT 2023
|
||
|
NCI_THESAURUS |
C271
Created by
admin on Fri Dec 15 16:45:49 GMT 2023 , Edited by admin on Fri Dec 15 16:45:49 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
205-001-1
Created by
admin on Fri Dec 15 16:45:49 GMT 2023 , Edited by admin on Fri Dec 15 16:45:49 GMT 2023
|
PRIMARY | |||
|
130-89-2
Created by
admin on Fri Dec 15 16:45:49 GMT 2023 , Edited by admin on Fri Dec 15 16:45:49 GMT 2023
|
PRIMARY | |||
|
7CS0WNO31M
Created by
admin on Fri Dec 15 16:45:49 GMT 2023 , Edited by admin on Fri Dec 15 16:45:49 GMT 2023
|
PRIMARY | |||
|
DTXSID7044213
Created by
admin on Fri Dec 15 16:45:49 GMT 2023 , Edited by admin on Fri Dec 15 16:45:49 GMT 2023
|
PRIMARY | |||
|
C90739
Created by
admin on Fri Dec 15 16:45:49 GMT 2023 , Edited by admin on Fri Dec 15 16:45:49 GMT 2023
|
PRIMARY | |||
|
m9447
Created by
admin on Fri Dec 15 16:45:49 GMT 2023 , Edited by admin on Fri Dec 15 16:45:49 GMT 2023
|
PRIMARY | |||
|
91558
Created by
admin on Fri Dec 15 16:45:49 GMT 2023 , Edited by admin on Fri Dec 15 16:45:49 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD